Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Aripiprazole Lauroxil Dosing Regimens in Schizophrenia
NCT02320032Phase 1Completed
- Sponsor
- Alkermes
- Start
- Dec 2014
- Primary completion
- Apr 2016
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aripiprazole lauroxil in schizophrenia (4 arms), sponsored by Alkermes. Primary endpoints: Area Under the Curve from time zero to last measurable concentration up to 45 weeks, Maximum Plasma Concentration up to 45 weeks and 1 more. Started Dec 2014; status: completed.
02
Drugs
aripiprazole lauroxil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02320032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02320032.